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Abstract 
Quantum dots (QDs) are a new class of flu-
orescent  probes  to  detect  biomarker  expres-
sion. The role of caveolin-1 (Cav-1) in tongue
squamous  cell  carcinoma  (TSCC)  is  still
unknown. This study aimed to investigate the
expression profile of Cav-1 in carcinogenesis
and development of TSCC by QDs immunoflu-
orescence histochemistry (QDs-IHC) and dis-
cuss  the  relationship  between  the  Cav-1
expression  and  the  clinicopathological  out-
comes.  QDs-IHC  was  used  to  detect  Cav-1
expression  in  tissue  microarrays  including
normal tongue mucosa (NTM; n=10), hyper-
plastic tongue mucosa (HTM; n=10), tongue
pre-cancer  lesions  (TPL;  n=15)  and  primary
tongue  squamous  cell  carcinoma  (PTSCC;
n=61). Correlations between the Cav-1 expres-
sion and clinicopathologic variables were eval-
uated  statistically.    Cells  positive  for  Cav-1
were clearly detected and bright images were
obtained in a fine, granular pattern at the cell
membrane and cytoplasm using QDs-IHC. The
rate of Cav-1 immunoreactivity increased pro-
gressively  from  NTM  (0%),  HTM  (0%),  TPL
(36%) to PTSCC (74%). When compared with
each other, there was statistical significance
among PTSCC, TPL and NTM as well as among
PTSCC, TPL and HTM. Moreover, Cav-1 expres-
sion level in PTSCC was correlated positively
with clinical stage and histologic grade.  QDs-
IHC could accurately detect protein location in
tongue  mucosa.  An  increased  expression  of
Cav-1  in  the  stepwise  carcinogenesis  from
NTM, HTM, TPL to PTSCC suggested that Cav-
1 might be an oncogene in the development of
tongue squamous cell carcinoma.    
Introduction
Oral  squamous  cell  carcinoma  (OSCC)  is
the most common malignant neoplasm of the
oral mucosa; it ranks among the top twelfth
most frequently diagnosed cancers worldwide.
In  China,  tongue  squamous  cell  carcinoma
(TSCC) predominates more than 95% of OSCC
and its incidence is increasing year by year.
However, the pathogenesis of TSCC is not yet
completely disclosed. Dysplastic lesions of the
oral cavity range from mild to moderate and
severe dysplasia, and the presence and degree
of dysplasia are often used to predict malig-
nant transformation. Moreover, the prognosis
for most patients with OSCC, of course includ-
ing TSCC, is usually related to clinical stage
and histologic grade.
1 Therefore, the identifi-
cation of effective biologic markers that corre-
late with the stepwise of carcinogenesis and
development  in  TSCC  is  very  important  to
understand this neoplasm.
Caveolin-1 (Cav-1), a 21-24 kDa protein is
the  major  structural  component  of  caveolae,
vesicular  invaginations  of  the  plasma  mem-
brane. Previous studies have implicated Cav-1
in the development of several human cancers,
but it appears to play quite different roles in
the development of these diseases: down-regu-
lation  of  Cav-1  expression  was  observed  in
breast, lung, colon and ovarian cancer;
2,3 other
studies  have  reported  that  Cav-1  expression
was  up-regulated  in  some  human  cancers,
such as prostate, esophagus, thyroid and pan-
creas cancers, and that this up-regulation was
associated with metastases and poor progno-
sis.
4-7 In OSCC as well, the role of Cav-1 still
remains controversial: two research groups
8,9
found that an increased Cav-1 expression plays
an important role in carcinogenesis and devel-
opment of OSCC. In contrast, some studies
10
disclosed that the inactivation of Cav-1 by a
mutation or by reduced expression might play
a role in the pathogenesis of oral cancer, which
indicated the value to explore Cav-1’s biphasic
functions  in  OSCC.  To  our  best  knowledge,
there  is  no  report  about  the  relationship
between Cav-1 expression and TSCC. Whether
Cav-1 acts as oncogene or tumor suppressor
gene in the development of TSCC derserves
new insights.
Semiconductor  quantum  dots  (QDs)  are
new  nanocrystal  semiconductor  fluorophores
consisting  of  a  cadmium  selenide  core  and
zinc  sulfide  or  cadmium  sulfide  shell.  As
described in previous publications,
11 QDs can
be used to target malignant tumors with high
specificity, when conjugated with biomolecular
affinity ligands, such as antibodies, peptides or
small molecules. Due to their novel optical and
electronic properties, such as high brightness,
stability and simplified multiple target label-
ing, QDs recently attracted attention for their
potential application in advanced biosensors,
bioanalytical assays and cell imaging.
12
In this report, using a new method QDs-IHC,
we  sought  to  investigate  the  expression  of
Cav-1 in normal tongue mucosa (NTM), hyper-
plastic tongue mucosa (HTM), tongue pre-can-
cer lesions (TPL) and TSCC, trying to elucidate
the  possible  role  of  Cav-1  in  carcinogenesis
and development of TSCC. 
Materials and Methods
Histological examination and tissue
microarray construction
We evaluated 96 cores, including 61 cases of
human TSCC, 10 cases of NTM, 10 cases of
HTM and 15 cases of TPL using human tissue
microarray (TMA) technology (Department of
Oral Pathology, School of Stomatology, Wuhan
University). The specimens and donors evalu-
ated  in  this  research  were  anonymous.  Two
board-certified  pathologists  re-confirmed  the
histopathologic  features  of  these  samples.
Histological diagnosis and grades of differenti-
ation were determined in accordance with the
World Health Organization (WHO) criteria for
oral tumors.
13 Concerning the TSCC cases, all
the samples were deriving from the tongue of
61 patients, 34 males and 27 females, with an
average age of 54.8 years; the histological dif-
ferentiation of TSCC was classified as “well”,
“moderate” or “poor”. The tumor (T) stages
were: T1-24, T2-34, T3-2, and T4-1. The neck
(N) stages were: N0-48, N1-13. A total of 61
samples were stage M0 (metastasis 0.)
All  the  tissues  were  taken  from  surgical
resection  prior  to  initial  topical  or  systemic
therapy.  They  were  fixed  in  10%  neutral
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buffered formalin for 24 hours and processed
using identical standard operating procedures
(SOPs).  Tissue  samples  were  arranged  in  6
columns of 16 rows for a total of 96 individual
cores (1.5 mm, 4 ʼm). Each slide has >95% tis-
sue core retention.
Immunofluorence by quantum dots
immunohistochemistry 
Four ʼm-thickness TMAs were deparaffined
in xylene and rehydrated in a graded series of
ethanol.  Immunofluorescence  histochemistry
was performed according to the manufactur-
er’s  instructions.  Antigen  retrieval  was  per-
formed using citric acid (10 mM, pH 6.0) at
95°C for 10 min and left to cool for 60 min.
TMAs were incubated with 2% bovine serum
albumin (BSA) (Sigma, St. Louis, MO, USA)
buffer  for  30  min  at  37°C.  The  slides  were
rinsed  3×  with  TBS-Tween  20  (TBS-T)  (5
min).  Sections  were  incubated  with  rabbit
anti-human Cav-1 polyclonal antibody (1:300
dilution, Santa Cruz, CA, USA) for 2h at 37°C,
followed by three washes with TBS-T (5 min),
then incubated with biotinylated goat anti-rab-
bit  IgG  (Zhongshan  Golden  Bridge
Biotechnology CO, LTD., Beijing, China) for 30
min  at  37°C,  and  rinsed  3×  with  TBS-T  (5
min).  Slides  were  incubated  with  2％ BSA
buffer for 10 min at 37°C before incubation
with  streptavidin-conjugated  QDs605  (1:100,
Wuhan  Jiayuan  Quantum  Dot  Co,  LTD.,
Wuhan, Hubei, China) in 2％ BSA for 30 min
at 37°C and rinsed 3× with TBS-T (5 min), the
edges sealed with 90% glycerine (Sigma, St.
Louis, MO, USA). The signal obtained from the
labeling of cells was detected by using fluores-
cence  microscopy.  The  QDs  signals  were
shown to be target specific, red, bright, and
photo stable. Cav-1 immunoreactivity was nor-
mally localized to fibroblasts and endothelial
cells of blood vessels in all tissue specimens
examined, which served as an internal quality
control in QDs-IHC. TBS instead of Cav-1 pri-
mary antibody served as negative controls.
A  reproducible  semiquantitative  analysis
14
was used to evaluate the expression level of
Cav-1 in tissue samples. The sections were ini-
tially  scanned  at  low  power,  and  areas  with
high and low staining intensity were selected.
At each selected field, cells were classified with
respect to staining intensity ranging from 0 to
4, and the percentage of cells for each staining
intensity was estimated by decimal equivalent
ranging from 0 to 1. A numerical value for Cav-
1 staining in each tissue section was then cal-
culated by multiplying the fraction of cells at
each staining intensity by the numerical value
of that intensity, resulting in scores ranging
from 0 to 4. Expression levels of each Cav-1 in
tumor samples were graded based on the total
score as follows: negative or low = score ≤1;
moderate  or  high  score＞1.  we  defined  the
cutoff  between  score  and  score＞1  because
score 1 level was the most significant patholog-
ic effect in clinicopathological features. Two
observers evaluated independently the results
of this method, without any knowledge of the
clinical data. Positive cells for Cav-1 were cell
membrane and cytoplasmic granular staining.
Statistical analysis
The c-
2 test and Fisher’s exact tests were
used  to  compare  differences  between  Cav-1
expression and different tongue lesion, which
is a clinical pathological parameter of PTSCC.
Statistical analysis was performed using SPSS
version  13  software  (SPSS  Inc,  Chicago,  IL,
USA). Type I error probability (2-sided) less
than or equal to 0.05 was considered the level
of significance for all statistical procedures.
Results
Immunofluorescence  by  QDs  analysis
revealed focal positive immunoreactivity for
Cav-1  in  normal  squamous  epithelium
(Figure  1A)  and  hyperplastic  squamous
epithelium (Figure 1B). Among 15 dysplastic
tissues, 5 showed moderate to high levels of
Cav-1 expression (score>1), characterized by
intensive immunoreactivity in the full thick-
ness of epithelium and all were diagnosed as
severe dysplasia. (Figure 1C). The left 10 tis-
sues  showed  Cav-1  expression  confined  to
basal  or  parabasal  cells  (Figure  1D).  In  all
sections  examined,  a  strong,  diffuse,  cyto-
plasmic  staining  pattern  in  the  endothelial
cells in the stroma vessels was detected, as
described previously. 
Among the primary tumors examined, mod-
erate  to  high  levels  of  Cav-1  expression
(score>1)  were  noted  in  45  tumors  (74%).
Tumor  cells  positive  for  Cav-1  were  clearly
detected and brighter images were obtained in
a fine, granular pattern at the surface mem-
brane  and  the  cytoplasm  (Figure  2A).
Interestingly, we observed the stronger posi-
tive signals in the peripheral cancer nests than
in the middle cancer nests (Figure 2A) and in
the  same  section  the  Cav-1  expression  in
tumor nests was more intensive than in dys-
plastic mucosa (Figure 2B). Even single cell
out of cancer nests positive for Cav-1 could be
clearly detected (Figure 2C). Negative control
showed negative reactivity for Cav-1 (Figure
2D).  The  poorly  differentiated  cells  of  these
tumors  with  high  levels  (score>2)  of  Cav-1
expression showed stronger diffuse cytoplas-
mic and cell surface staining than that showed
by well differentiated tumor cells with low lev-
els of expression (score≤1) (Figure 3A-C). 
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Figure 1. Cav-1 expression by QDs-IHC in normal, hyperplastic and displastic tongue
mucosa. (A) Focal expression of Cav-1 in normal tongue mucosa (QDs-IHC×200). (B)
Focal expression of Cav-1 in hyperplastic tongue mucosa and internal control showed a
strong, diffuse, cytoplasmic staining pattern in the endothelial cells in the stroma vessels
(QDs-IHC×200). (C) Almost full thickness of epithelium in severely dysplasitic tongue
mucosa is positive for Cav-1(QDs-IHC×400). (D) Cav-1 expression confined to basal or
parabasal cells in mild or moderate dysplastic tongue mucosa (QDs-IHC×200).[European Journal of Histochemistry 2010; 54:e20] [page 101]
Statistically,  Cav-1  expression  in  the  TPL
and PTSCC showed significant increase com-
pared with that of normal mucosa and hyper-
plastic  mucosa  respectively,  (P＜0.01,  Table
1). Cav-1 expression of PTSCC was also signif-
icantly higher compared with TPL (P＜0.01,
Table 1). In PTSCC, the clinicopathologic vari-
ables are listed in Table 2. Statistical correla-
tion was found between the enhanced Cav-1
expression  and  the  degree  of  histological
grades  (“well”,  “moderate”  and  “poor”,
P<0.05).  In  addition,  altered  expression  of
Cav-1 was associated with the T stage and N
classification. In contrast, there was no corre-
lation between the positivity of Cav-1 expres-
sion and gender and age.
Discussion
Determination of the expression and spatial
distribution of molecular epitopes, or antigens,
in patient tissue specimens has substantially
improved  the  pathologist's  ability  to  classify
disease processes. Certain tumor pathophysi-
ologies are marked by characteristic increased
or decreased expression of some proteins. The
primary goals of tumor research are to identify
these molecular factors, among which Cav-1
has attracted attention because of its altered
expression  patterns  in  tumour  cells,  which
contribute  to  tumorigenesis  and  tumor  pro-
gression. In this report, we have used a new
QDs-IHC method to observe the expression of
Cav-1 in stepwise carcinogenesis and develop-
ment  of  TSCC  on  basic  fluorescence  micro-
scope.   
QDs, a novel inorganic fluorophores, may be
cross-linked to biomolecules such antibodies,
oligonucleotides or small molecule ligands to
render them specific to biological targets. Due
to their novel optical and electronic properties,
the use of multicolor QDs probes is considered
one of the most important and clinically rele-
vant applications. They have been received as
technological marvels with such characteris-
tics able to greatly improve biological imaging
and detection. A previous study
15 revealed that
QDs can be applied to formalin-fixed, paraffin-
embedded  tissues;  this  technique  achieves
sensitivity and specificity levels that are suffi-
cient  for  the  potential  application  of  known
expression signatures to biopsy specimens in
a semi-quantitative way, while the semi-auto-
mated nature of this method enables applica-
tion  to  high-throughput  studies.  Some
researchers
16 demonstrated  that  QDs  probe
could  be  used  for  multiplexed  profiling  of
molecular biomarkers, and ultimately for cor-
relation with disease progression. Our previ-
ous study
17 also indicated QDs-IHC is sensitive
and specific in detecting the protein in paraf-
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Table 2. Relationship between clinicopathologic features and Caveolin-1 expression in
primary tongue squamous cell carcinoma by QDs-IHC.
Variable Cav-1 Score P
≤1.0 ＞1
Gender
Male 7 27 P＞0.05
Female 9 18
Age
≥60 6 18 P＞0.05
＜60 10 27
T status*
T1 14 10 P＜0.05
T2+T3+T4 2 35
N status°
N0 16 32 P＜0.05
N1 0 13
Differentiation
Well 15 18 P＜0.05
Moderate 1 16
Poor 0 11
*Tumor stage, size or direct extent of the primary tumor; °Neck stage, degree of spread to neck lymph nodes.
Figure 2. Cav-1 expression by QDs-IHC in PTSCC. (A) Tumor cells in PTSCC positive
for Cav-1 were obtained in a fine, granular pattern at the surface membrane and the cyto-
plasm; in the peripheral cancer nests were observed stronger positive signals than in the
middle cancer nests (QDs-IHC×400). (B) In the same section, the Cav-1 expression in
tumor nests was more intensive than in dysplastic mucosa (QDs-IHC×200). (C) Single
tumor cell in PTSCC positive for Cav-1 could be clearly detected (QDs-IHC×400). (D)
Negative control showed negative reactivity for Cav-1 (QDs-IHC×100).
Table 1. Correlations of Cav-1 expression among normal tongue mucosa, hyperplastic
tongue mucosa, tongue premalignant lesion and tongue squamous cell carcinoma. 
Groups Cav-1 Score P
≤1.0 ＞1






Tongue squamous cell carcinoma
c 16 45 P
ac<0.01
Pab, normal and hyperplastic tongue mucosa vs premalignant lesion; Pbc, premalignant lesion vs tongue squamous cell carcinoma; 
Pac, normal and hyperplastic tongue mucosa vs tongue squamous cell carcinoma.[page 102] [European Journal of Histochemistry 2010; 54:e20]
fin-embedded  lung  tissue.  Our  present  data
indicate that Cav-1 expression with moderate
to high levels using QDs-IHC in 74% of TSCC;
positive  signals  were  strong  and  clear  with
clean background, indicating QDs-IHC might
be an efficient method for protein detection in
tongue samples.
Cav-1 is the principal component of caveo-
lae,  which  are  special  invaginated  micro-
domains of the plasma membrane present in
most mammalian cells.
18 It plays a key role in
the regulation of several signal transduction
molecules and attracts more and more atten-
tion due to its paradoxical biological functions
in malignant tumors. In this study, we noted
for  the  first  time  a  progressive  increase  of
Cav-1  expression  from  NTM,  HTM,  TPL  to
PTSCC (a series of tissues ranging from nor-
mal  to  neoplastic),  which  is  a  trend  of
increased expression of Cav-1 in the stepwise
tongue carcinogenesis. Moreover, in the same
sample the Cav-1 expression in tumor nests
was  more  intensive  than  that  in  dysplasia
mucosa. The up-regulated expression of Cav-1
observed in the present study using QDs-IHC
was  similar  to  that  reported  in  studies  of
esophageal  squamous  cell  carcinoma,
4
prostate cancer
5 and pancreatic cancer.
7 It has
been suggested that the secreted fraction of
Cav-1 is associated with cell released micro  -
vesicles,  which  are  able  to  confer  tumori-
genicity in vitro as well as in vivo. Our study
showed  that  up-regulated  Cav-1  expression
was associated with advanced clinical stage
and  high-grade  malignancy  of  TSCC,  while
Nakatani et al.
9 found that the level of Cav-1
expression  did  not  differ  among  stages  or
other clinical parameters, except for the level
of Cav-1 expression between the well-differen-
tiated  and  poorly  differentiated  groups.  The
reasons might be as follows: i) different meth-
ods; our group just used a different method in
the  present  study.  ii)  different  samples;
Nakatani et al.
9 used OSCC samples in differ-
ent sites including tongue, maxilla, mandibu-
lar and floor of mouth, while all of our samples
arised from the tongue. iii) a different score
system for the immunoevaluation used in the
present  study.  In  addition,  in  the  present
research,  in  PTSCC  were  observed  stronger
positive signals in the peripheral cancer nests
than  in  the  middle  cancer  nests;  this  is  in
agreemetn with the results of previous stud-
ies,
19,20 showing  that  Cav-1  is  preferentially
expressed  in  tumor  cells  with  basal-like
immunophenotype,  as  defined  by  cDNA
microarrays or immunohistochemistry.
On the other hand, a previous study
10 dis-
closed that the inactivation of Cav-1 by a muta-
tion or by reduced expression might play a role
in  the  pathogenesis  of  oral  cancer.  Some
authors also found that Cav-1 might be a tumor
suppressor, because of its decreased expres-
sion in a variety of cancer such as breast carci-
noma, colon carcinoma, uterine cervical carci-
noma, sarcoma of head and neck.
21 Lee and col-
leagues
22 suggested that the diverse effects of
Cav-1 might be simply mediated by the differ-
ent regions of Cav-1 molecule and might be
dependent on the levels of other molecules that
are co-expressed with Cav-1.
Although the sample size for tongue epithe-
lial dysplasia in the current study is insuffi-
cient for statistical analysis on Cav-1 expres-
sion, 10 “mild” to “moderate” tongue epithelial
dysplasia  revealed  basal  or  parabasal  cells
staining, whereas 5 “severe” tongue epithelial
dysplasia samples revealed the whole epithe-
lial  layer  staining.  This  staining  pattern  of
upward extension of Cav-1 protein may sug-
gest that the Cav-1 expression was consistent
with the severity of oral epithelial dysplasia. 
In conclusion, our results may suggest that
Cav-1 protein is one of the oncogenes that con-
tribute to the carcinogenesis and development
of TSCC. Whether Cav-1 is an important pre-
dictor or prognosis for survival still awaits the
extension of clinical follow-up.  
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